Literature DB >> 7962541

Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus.

Y W Tang1, B S Graham.   

Abstract

Upon respiratory syncytial virus (RSV) challenge, mice previously immunized intramuscularly with inactivated whole virus express a Th2-like pattern of cytokine mRNA, while mice immunized with live virus intranasally express a Th1-like pattern. In this study, we evaluated the effects of anti-IL-4 treatment on the induction of immune responses after immunization. Mice treated with anti-IL-4 at the time of immunization with inactivated RSV had reduced clinical illness after live virus challenge, as measured by weight loss, illness score, and virus replication. This was associated with an augmented CD8+ cytotoxic T lymphocyte (CTL) activity, increased expression of IFN-gamma mRNA relative to IL-4 mRNA, and a higher titer of RSV-specific IgG2a in the anti-IL-4 treated mice before challenge. Anti-IL-4 administration at the time of challenge had no effects on illness, immunoglobulin isotype, or cytokine patterns. These results suggest that inhibition of IL-4 action at immunization can shift the selective activation of lymphocytes to a more Th1-like response. This cytokine milieu is associated with augmented CTL activity, which may be the factor responsible for rapid viral clearance and reduced illness at the time of remote RSV challenge.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7962541      PMCID: PMC294611          DOI: 10.1172/JCI117546

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  Anti-IL-4 diminishes in vivo priming for antigen-specific IL-4 production by T cells.

Authors:  A Gross; S Z Ben-Sasson; W E Paul
Journal:  J Immunol       Date:  1993-03-15       Impact factor: 5.422

2.  Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance.

Authors:  L Romani; S Mocci; C Bietta; L Lanfaloni; P Puccetti; F Bistoni
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

3.  Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals.

Authors:  M Clerici; F T Hakim; D J Venzon; S Blatt; C W Hendrix; T A Wynn; G M Shearer
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

Review 4.  New concepts about the mast cell.

Authors:  S J Galli
Journal:  N Engl J Med       Date:  1993-01-28       Impact factor: 91.245

5.  Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus.

Authors:  A H Cherrie; K Anderson; G W Wertz; P J Openshaw
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

6.  Differential CD4 T cell activation in measles.

Authors:  D E Griffin; B J Ward
Journal:  J Infect Dis       Date:  1993-08       Impact factor: 5.226

7.  Resistance of mice deficient in IL-4 to retrovirus-induced immunodeficiency syndrome (MAIDS)

Authors:  O Kanagawa; B A Vaupel; S Gayama; G Koehler; M Kopf
Journal:  Science       Date:  1993-10-08       Impact factor: 47.728

8.  Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus.

Authors:  B S Graham; G S Henderson; Y W Tang; X Lu; K M Neuzil; D G Colley
Journal:  J Immunol       Date:  1993-08-15       Impact factor: 5.422

9.  Disruption of the murine IL-4 gene blocks Th2 cytokine responses.

Authors:  M Kopf; G Le Gros; M Bachmann; M C Lamers; H Bluethmann; G Köhler
Journal:  Nature       Date:  1993-03-18       Impact factor: 49.962

10.  Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins.

Authors:  W H Alwan; F M Record; P J Openshaw
Journal:  J Immunol       Date:  1993-06-15       Impact factor: 5.422

View more
  50 in total

1.  Predominant type-2 response in infants with respiratory syncytial virus (RSV) infection demonstrated by cytokine flow cytometry.

Authors:  K Bendelja; A Gagro; A Bace; R Lokar-Kolbas; V Krsulovic-Hresic; V Drazenovic; G Mlinaric-Galinovic; S Rabatic
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 2.  Pathogenesis of respiratory syncytial virus infection in the murine model.

Authors:  R Stokes Peebles; Barney S Graham
Journal:  Proc Am Thorac Soc       Date:  2005

3.  Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus.

Authors:  J E Fischer; J E Johnson; R K Kuli-Zade; T R Johnson; S Aung; R A Parker; B S Graham
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Mapping and characterization of the primary and anamnestic H-2(d)-restricted cytotoxic T-lymphocyte response in mice against human metapneumovirus.

Authors:  Guillermina A Melendi; Fidel Zavala; Ursula J Buchholz; Guy Boivin; Peter L Collins; Steven R Kleeberger; Fernando P Polack
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

5.  Molecular cloning of cat interleukin-4.

Authors:  V E Schijns; C M Wierda; E J van Dam; T W Vahlenkamp; M C Horzinek
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

6.  Modification of the Sendai virus-specific antibody and CD8+ T-cell responses in mice homozygous for disruption of the interleukin-4 gene.

Authors:  X Y Mo; M Y Sangster; R A Tripp; P C Doherty
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

7.  Gene expression differences in lungs of mice during secondary immune responses to respiratory syncytial virus infection.

Authors:  Annemieke Schuurhof; Louis Bont; Jeroen L A Pennings; Hennie M Hodemaekers; Piet W Wester; Annemarie Buisman; Lia C G H de Rond; Myra N Widjojoatmodjo; Willem Luytjes; Jan L L Kimpen; Riny Janssen
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

8.  Cutting edge: Eosinophils do not contribute to respiratory syncytial virus vaccine-enhanced disease.

Authors:  Elaine M Castilow; Kevin L Legge; Steven M Varga
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

9.  Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination.

Authors:  Elaine M Castilow; Steven M Varga
Journal:  Future Virol       Date:  2008       Impact factor: 1.831

10.  Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination.

Authors:  B S Graham; R C Kines; K S Corbett; J Nicewonger; T R Johnson; M Chen; D LaVigne; J N Roberts; N Cuburu; J T Schiller; C B Buck
Journal:  Mucosal Immunol       Date:  2010-06-16       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.